Skip to main content

Susvimo

Generic name: ranibizumab
Dosage form:  injection for intravitreal use via Susvimo ocular implant
Drug class: Anti-angiogenic ophthalmic agents

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 17, 2023.

What is Susvimo?

Susvimo is a prescription medicine used to treat adults with Neovascular (wet) Age-related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).

It is not known if Susvimo is safe and effective in children.

Important information

Susvimo (ranibizumab injection) is delivered into the eye using the Susvimo implant. The Susvimo implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause serious side effects including:

Who should not receive Susvimo?

Do not receive Susvimo if you:

Talk to your healthcare provider before receiving this Susvimo if you have any of these conditions.

Before receiving Susvimo

Before receiving Susvimo, tell your healthcare provider about all of your medical conditions, including if you:

What other drugs will affect Susvimo?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive Susvimo?

Your healthcare provider will give you instructions to follow after the implant insertion, the refill procedure, and the implant removal. The instructions may include:

After the Implant Insertion:

After the Implant Removal:

These are not all the instructions you may receive from your healthcare provider. Following all post-procedure instructions may help prevent serious side effects or keep side effects from becoming more serious. See Important information.

What should I avoid while receiving Susvimo?

Dosing information

- The recommended dose of Susvimo (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 24 weeks (approximately 6 months). Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary.

Use: treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.

Susvimo side effects

See Important information.

In addition to those side effects listed on page one, the Susvimo implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause other serious side effects including:

The most common side effects include:

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Genentech at 1-888-835-2555.

General information about the safe and effective use of Susvimo.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Susvimo?

Active ingredient: ranibizumab
Inactive ingredients: histidine HCl, polysorbate 20, sucrose.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.